argenx SE (NASDAQ:ARGX) Stake Boosted by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP grew its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 481,305 shares of the company's stock after acquiring an additional 931 shares during the period. argenx accounts for approximately 10.3% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 3rd biggest holding. Paradigm Biocapital Advisors LP owned approximately 0.79% of argenx worth $296,003,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Assenagon Asset Management S.A. grew its stake in shares of argenx by 21.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock valued at $21,497,000 after buying an additional 6,161 shares during the period. Park Avenue Securities LLC raised its stake in shares of argenx by 40.0% in the fourth quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock worth $1,042,000 after purchasing an additional 484 shares during the last quarter. Ritholtz Wealth Management raised its stake in shares of argenx by 85.5% in the fourth quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after purchasing an additional 414 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of argenx by 10.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 489 shares of the company's stock worth $301,000 after purchasing an additional 45 shares during the last quarter. Finally, Ballentine Partners LLC increased its position in shares of argenx by 21.5% during the fourth quarter. Ballentine Partners LLC now owns 536 shares of the company's stock valued at $330,000 after acquiring an additional 95 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Oppenheimer lifted their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Baird R W upgraded argenx from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, William Blair reiterated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $698.11.

argenx Trading Up 1.2%

Shares of ARGX traded up $6.68 during midday trading on Monday, reaching $572.31. The stock had a trading volume of 122,521 shares, compared to its average volume of 324,147. The company's 50-day moving average is $591.63 and its 200 day moving average is $613.54. argenx SE has a 12-month low of $356.38 and a 12-month high of $678.21. The company has a market capitalization of $34.95 billion, a price-to-earnings ratio of -650.35 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Research analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.